Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK4524101 |
Synonyms | |
Therapy Description |
GSK4524101 inhibits DNA polymerase theta, which may prevent the repair of DNA-double stranded breaks, resulting in decreased tumor cell proliferation (Cancer Res (2024) 84 (7_Supplement): CT169, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK4524101 | GSK 4524101|GSK-4524101 | GSK4524101 inhibits DNA polymerase theta, which may prevent the repair of DNA-double stranded breaks, resulting in decreased tumor cell proliferation (Cancer Res (2024) 84 (7_Supplement): CT169, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06077877 | Phase Ib/II | GSK4524101 + Niraparib GSK4524101 Niraparib | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors | Recruiting | USA | CAN | 0 |